FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- BioRestorative Therapies, Inc. obtained approval from the FDA on August 6, 2025.Sub-event
FDA approved multiple Alnylam therapeutics for the company based in Cambridge.1 source
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- FDA
Related events
- FDA approved a new cancer drug in Massachusetts on October 21, 2026.
- Alnylam Pharmaceuticals and Oncocyte are being compared for investment, and MarketBeat reports analyst ratings for Oncocyte.
- The FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors